Scarica l'app Stockscreener
16.53
1.90%
-0.32
Pre-mercato:
17.03
0.50
+3.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
Where are the Opportunities in (ATRA) - Stock Traders Daily
Here's Why You Should Consider Buying Atara Biotherapeutics Stock - Barchart
Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) high institutional ownership speaks for itself as stock continues to impress, up 27% over last week - Yahoo Finance
Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Target Price at $18.75 - MarketBeat
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Holdings Increased by State Street Corp - Defense World
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why - Yahoo Finance
Biotech Stocks Facing FDA Decision In January 2025 - Nasdaq
(ATRA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Atara Biotherapeutics Amends and Restates Bylaws in Recent Board Decision - Defense World
Atara Biotherapeutics (NASDAQ:ATRA) Research Coverage Started at Rodman & Renshaw - Defense World
Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors - Marketscreener.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Bought by Fmr LLC - Defense World
Atara Biotherapeutics (NASDAQ:ATRA) Raised to “Strong-Buy” at RODMAN&RENSHAW - Defense World
RODMAN&RENSHAW Upgrades Atara Biotherapeutics (NASDAQ:ATRA) to "Strong-Buy" - MarketBeat
Rodman & Renshaw bullish on Atara stock, sees upside in CAR-T autoimmune therapies - Investing.com Canada
Rodman & Renshaw Initiates Coverage of Atara Biotherapeutics (ATRA) with Buy Recommendation - MSN
Atara Biotherapeutics (NASDAQ:ATRA) Coverage Initiated at Rodman & Renshaw - MarketBeat
When (ATRA) Moves Investors should Listen - Stock Traders Daily
Head to Head Contrast: Atara Biotherapeutics (NASDAQ:ATRA) versus Fresh Tracks Therapeutics (NASDAQ:FRTX) - Defense World
Rajani DinavahiChief Medical Officer | Atara Biotherapeutics - Los Angeles Times
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $16.67 Consensus PT from Analysts - MarketBeat
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Sold by Centiva Capital LP - MarketBeat
(ATRA) Investment Report - Stock Traders Daily
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
Atara Biotherapeutics CEO sells shares worth $18,633 By Investing.com - Investing.com South Africa
Atara biotherapeutics CFO Eric Hyllengren sells $15,274 in stock By Investing.com - Investing.com Nigeria
Atara biotherapeutics EVP sells $11,198 in stock By Investing.com - Investing.com Australia
Atara biotherapeutics CFO Eric Hyllengren sells $15,274 in stock - Investing.com India
Atara biotherapeutics EVP sells $11,198 in stock - Investing.com India
Atara Biotherapeutics CEO sells shares worth $18,633 - Investing.com
FUJIFILM Diosynth Biotechnologies Celebrates the Expansion Completion at its California Cell Therapy Facility - GlobeNewswire Inc.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
How the (ATRA) price action is used to our Advantage - Stock Traders Daily
EcoR1 Capital, LLC Increases Stake in Atara Biotherapeutics Inc - GuruFocus.com
Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Atara Biotherapeutics Reports Q3 2024 Financial Progress - TipRanks
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference - Business Wire
Atara Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stifel raises Atara Bio shares target, keeps hold rating ahead of clinical data - Investing.com UK
Atara Biotherapeutics (NASDAQ:ATRA) Price Target Raised to $21.00 - MarketBeat
Atara Biotherapeutics: Q3 Earnings Snapshot - Houston Chronicle
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q3 Revenue $40.2M - Marketscreener.com
Atara Bio Q3 Revenue Soars 1,814% to $40.2M, FDA Decision Looms for Tab-cel Drug | ATRA Stock News - StockTitan
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress - Business Wire
(ATRA) On The My Stocks Page - Stock Traders Daily
Atara Biotherapeutics (ATRA) to Release Quarterly Earnings on Tuesday - MarketBeat
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement - Simply Wall St
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - Business Wire
0.08%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):